Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Trials & Filings in Brief: Nov. 5, 2013 | Contract Pharma

What are you searching for?

Sign in
Breaking News, Trials & Filings

Trials & Filings in Brief: Nov. 5, 2013

Aeterna Zentaris, Alcobra, CEL-SCI, Genkyotex, ImmunoGen, Immunomedics, Keryx, Omeros, OncoMed, Repros, Reviva, Serodus, Shire

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Preclinical
Omeros gets good results for AMD mAb . . . read more

Phase I
ImmunoGen starts ADC trial . . . read more

OncoMed hits dose escalation milestone . . . read more

Phase II
Alcobra completes ADHD enrollment . . . read more

Genkyotex starts NOX inhibitor trial . . . read more

Keryx hits targets in NDD-CKD trial . . . read more

Serodus enrolls patients for ISH trial . . . read more

Phase III
CEL-SCI receives positive safety news for Multikine trial . . . read more

Reviva cleared to advance candidate against schizophrenia . . . read more

Shire’s Vynase performs well against binge eating . . . read more

Filings
Aeterna Zentaris files NDA for AGHD . . . read more

Immunomedics gais TROP-2 antibody patent . . . read more

Repros discusses endpoints with FDA . . . read more

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics